Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone-Atomoxetine Interaction.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
02 2020
Historique:
received: 17 09 2019
accepted: 12 10 2019
pubmed: 7 12 2019
medline: 22 6 2021
entrez: 7 12 2019
Statut: ppublish

Résumé

There is a paucity of clinical trials for the treatment of pediatric insomnia. This study was designed to predict the doses of trazodone to guide dosing in a clinical trial for pediatric insomnia using physiologically-based pharmacokinetic (PBPK) modeling. Data on the pharmacokinetics of trazodone in children are currently lacking. The interaction potential between trazodone and atomoxetine was also predicted. Doses predicted in the following age groups, with exposures corresponding to adult dosages of 30, 75, and 150 mg once a day (q.d.), respectively, were: (i) 2- to 6-year-old group, doses of 0.35, 0.8, and 1.6 mg/kg q.d.; (ii) >6- to 12-year-old group, doses of 0.4, 1.0, and 1.9 mg/kg q.d.; (iii) >12- to 17-year-old group, doses of 0.4, 1.1, and 2.1 mg/kg q.d. An interaction between trazodone and atomoxetine was predicted to be unlikely. Clinical trials based on the aforementioned predicted dosing are currently in progress, and pharmacokinetic data obtained will enable further refinement of the PBPK models.

Identifiants

pubmed: 31808613
doi: 10.1002/psp4.12480
pmc: PMC7020267
doi:

Substances chimiques

Antidepressive Agents, Second-Generation 0
Atomoxetine Hydrochloride 57WVB6I2W0
Trazodone YBK48BXK30

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-86

Informations de copyright

© 2019 ANGELINI S.p.A. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

Références

Clin Pharmacol Ther. 2014 May;95(5):473-6
pubmed: 24747234
Clin Pharmacokinet. 2015 Jan;54(1):117-27
pubmed: 25260695
Br J Clin Pharmacol. 1983 Oct;16(4):371-6
pubmed: 6626432
Pharmacotherapy. 2016 Jan;36(1):84-98
pubmed: 26799351
Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):861-83
pubmed: 23040905
Pharm Res. 2007 May;24(5):918-33
pubmed: 17372687
Arch Pediatr Adolesc Med. 2008 Apr;162(4):323-9
pubmed: 18391140
Sleep. 2009 Dec;32(12):1566-78
pubmed: 20041592
Paediatr Drugs. 2010 Apr 1;12(2):75-84
pubmed: 20218744
Clin Pharmacokinet. 2006;45(9):931-56
pubmed: 16928154
Drug Metab Dispos. 2010 Jul;38(7):1147-58
pubmed: 20368326
J Clin Pharmacol. 2003 Apr;43(4):414-22
pubmed: 12723462
J Pharmacol Exp Ther. 2004 Feb;308(2):410-8
pubmed: 14610241
Drug Metab Dispos. 2008 Dec;36(12):2405-9
pubmed: 18775982
Drug Metab Dispos. 2003 Jan;31(1):98-107
pubmed: 12485958
Clin Pharmacol Ther. 2009 Jun;85(6):644-50
pubmed: 19242403
Neuropediatrics. 2015 Jun;46(3):199-210
pubmed: 25918987
Drugs Context. 2015 Oct 08;4:212290
pubmed: 26576188
J Child Psychol Psychiatry. 2018 May;59(5):489-508
pubmed: 28921528
Expert Opin Pharmacother. 2012 Aug;13(12):1707-17
pubmed: 22712761
Clin Pharmacol Ther. 1987 Aug;42(2):193-200
pubmed: 3608351
Psychopharmacology (Berl). 1999 Jul;145(1):113-22
pubmed: 10445380
Curr Pharm Des. 2015;21(23):3343-51
pubmed: 26088119
Arzneimittelforschung. 1976;26(11):2084-9
pubmed: 1037253
Pharmacol Toxicol. 1993 Apr-May;72(4-5):286-9
pubmed: 8372048
Int J Clin Pharmacol Ther. 2011 Dec;49(12):730-43
pubmed: 22122815
Clin Pharmacokinet. 2013 Dec;52(12):1085-100
pubmed: 23818090
Br J Clin Pharmacol. 2005 Jun;59(6):663-9
pubmed: 15948929
Drug Metab Dispos. 1998 Jun;26(6):572-5
pubmed: 9616194
Eur J Pharm Sci. 2014 Jun 16;57:240-9
pubmed: 24060671
J Clin Pharmacol. 2010 Dec;50(12):1438-49
pubmed: 20173086
CPT Pharmacometrics Syst Pharmacol. 2014 Oct 22;3:e150
pubmed: 25353188
Pharmacol Toxicol. 1992 Aug;71(2):150-3
pubmed: 1438031

Auteurs

Laura Oggianu (L)

Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy.

Alice B Ke (AB)

Simcyp Division, Certara UK, Sheffield, UK.

Manoranjenni Chetty (M)

Simcyp Division, Certara UK, Sheffield, UK.

Rossella Picollo (R)

Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy.

Vanessa Petrucci (V)

Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy.

Fabrizio Calisti (F)

Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy.

Fabio Garofolo (F)

Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy.

Serena Tongiani (S)

Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH